Buscar resultados de ensayos clínicos

Patrocinado por

Liposarcoma - 29 Studies Found

Estado Estudiar
Active, not recruiting Nombre del estudio: Brostallicin Clinical Trial for Myxoid Liposarcoma
Condición: Myxoid Liposarcoma
Fecha: 2008-03-03
Intervenciones: Drug: Brostallicin Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at
Completed Nombre del estudio: Ph II Cabazitaxel DD Liposarcoma
Condición: Dedifferentiated Liposarcoma
Fecha: 2013-07-30
Intervenciones:
  • Drug: Cabazitaxel Other Name:

Completed Nombre del estudio: Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
Condición: Liposarcoma
Fecha: 2015-01-05
Intervenciones:
  • Drug: HDM201
  • Drug: LEE011
Completed Nombre del estudio: Selinexor in Advanced Liposarcoma
Condición: Dedifferentiated Liposarcoma
Fecha: 2015-10-13
Intervenciones:
  • Drug: Selinexor Selinexor 60mg
Completed Nombre del estudio: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Condición: Liposarcoma,Myxoid
Fecha: 2007-12-20
Intervenciones:
  • Drug: Trabectedin Trabectedin

Recruiting Nombre del estudio: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
Condición: Liposarcoma
Fecha: 2014-09-24
Intervenciones: Drug: efatutazone Given PO
Completed Nombre del estudio: Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas
Condición: Myxoid Liposarcoma of Soft Tissue
Fecha: 2014-03-06
Intervenciones: Radiation: dose reduction of preoperative radiotherapy in MLS A: The primary sarcoma in case of non-meta
Completed Nombre del estudio: Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Condición:
  • Liposarcoma
  • Surgically Unresectable Lipos
    Fecha: 2012-01-06
    Intervenciones: Drug: pazopanib Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administ
Completed Nombre del estudio: MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Condición:
  • Liposarcoma
  • Metastatic Liposarcoma
    Fecha: 2016-11-29
    Intervenciones: Drug: MGCD516 Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, po
Withdrawn Nombre del estudio: Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
Condición: Dedifferentiated Liposarcoma
Fecha: 2009-09-01
Intervenciones: Drug: IPI-504 IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatmen
Next >>>